ORG Wealth Partners LLC Invests $100,000 in Oscar Health, Inc. (NYSE:OSCR)

ORG Wealth Partners LLC purchased a new position in shares of Oscar Health, Inc. (NYSE:OSCR) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 7,434 shares of the company’s stock, valued at approximately $100,000.

Several other institutional investors have also modified their holdings of the company. Nordea Investment Management AB purchased a new stake in shares of Oscar Health during the 4th quarter worth approximately $1,056,000. JPMorgan Chase & Co. lifted its stake in Oscar Health by 68.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,309,150 shares of the company’s stock valued at $48,977,000 after buying an additional 938,742 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in Oscar Health in the 3rd quarter valued at approximately $600,000. Geode Capital Management LLC lifted its stake in Oscar Health by 11.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,339,640 shares of the company’s stock valued at $92,062,000 after buying an additional 455,205 shares in the last quarter. Finally, Barclays PLC lifted its stake in Oscar Health by 217.5% in the 3rd quarter. Barclays PLC now owns 325,818 shares of the company’s stock valued at $6,911,000 after buying an additional 223,189 shares in the last quarter. Hedge funds and other institutional investors own 75.70% of the company’s stock.

Oscar Health Trading Down 7.7 %

Shares of OSCR opened at $14.12 on Friday. The stock has a fifty day moving average of $15.10 and a two-hundred day moving average of $16.89. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.73 and a current ratio of 0.73. The company has a market capitalization of $3.49 billion, a PE ratio of -235.29 and a beta of 1.70. Oscar Health, Inc. has a fifty-two week low of $9.70 and a fifty-two week high of $23.79.

Oscar Health (NYSE:OSCR) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.02). The firm had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.33 billion. Oscar Health had a return on equity of 2.79% and a net margin of 0.35%. The company’s quarterly revenue was up 68.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.29) earnings per share. As a group, analysts forecast that Oscar Health, Inc. will post -0.01 EPS for the current year.

Insider Transactions at Oscar Health

In related news, CAO Victoria Baltrus sold 8,078 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $18.08, for a total transaction of $146,050.24. Following the completion of the sale, the chief accounting officer now directly owns 146,036 shares of the company’s stock, valued at approximately $2,640,330.88. This represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Thrive Partners Vii Growth Gp, purchased 420,819 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were acquired at an average cost of $13.68 per share, with a total value of $5,756,803.92. Following the completion of the transaction, the director now owns 5,452,081 shares in the company, valued at $74,584,468.08. This trade represents a 8.36 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 1,055,478 shares of company stock worth $14,432,852 and sold 103,610 shares worth $1,847,519. Insiders own 25.11% of the company’s stock.

Analyst Upgrades and Downgrades

OSCR has been the topic of a number of recent research reports. UBS Group initiated coverage on Oscar Health in a research note on Monday, October 7th. They issued a “neutral” rating and a $23.00 target price on the stock. Bank of America lowered Oscar Health from a “neutral” rating to an “underperform” rating and reduced their target price for the company from $21.00 to $13.50 in a research note on Wednesday, November 6th. Finally, Jefferies Financial Group initiated coverage on Oscar Health in a research note on Tuesday, December 10th. They issued an “underperform” rating and a $12.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Oscar Health currently has a consensus rating of “Hold” and a consensus target price of $21.56.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.